All Questions
How Does The Coulter Principle Count Cells? Key Insights For Ivd Reagents
Learn how electrical impedance & the Coulter principle count blood cells, and why diluents & lysing agents are crucial for IVD reagent accuracy.
What Pharmacogenomic Considerations For Cyp3A5 And Cyp3A4 Govern Transplant Assay Design? Optimize Your Ivd Panel
Learn how CYP3A5 and CYP3A4 PGx considerations guide organ transplant genotyping assay design for precise tacrolimus dosing and IVD compliance.
Why Is Combined Multiplex Testing Of Tpmt And Nudt15 Necessary For Thiopurine Safety Panels? Dual-Gene Guide
Discover why combining TPMT and NUDT15 in multiplex IVD panels is critical to eliminate thiopurine toxicity blind spots across populations.
How Dpyd Variant Screening Informs Assay Design For Toxicity Risk: Key Insights For Ivd Kit Optimization
Discover how DPYD variant screening shapes molecular diagnostic assay design, target selection, enzyme fidelity, and reliable IVD kit manufacturing.
Which Key Genetic Variant Should Be In Statin-Myopathy Diagnostic Panels & What Is Its Functional Effect?
Learn why SLCO1B1 rs4149056 is the core variant for statin-myopathy risk panels, its functional effect on OATP1B1, and clinical panel design.
How Ugt1A1*28 Structure Drives Ivd Tech Selection: A Guide For Kit Developers
Learn how UGT1A1*28 TA repeat structure dictates IVD technology selection—comparing CE, qPCR, and NGS for optimal assay development.
What Analytical Limitation Must Developers Address Using Hcp5 For Hla-B*57:01 Kits? Cnv Risk Explained
Learn how CNV deletions cause false negatives in HCP5 (rs2395029) HLA-B*57:01 screening kits and explore strategies to build robust IVD assays.
Why Is Genomic Dna Genotyping Preferred Over Enzyme Activity Testing For Thiopurine Toxicity Risk Management?
Learn why genomic DNA genotyping outpaces enzyme activity testing for thiopurine toxicity risk, offering superior sample stability and accuracy.
Why Is Molecular Genotyping Preferable For Female G6Pd Testing? Bypass Lyonization In Ivd Assays
Discover why molecular genotyping bypasses X-inactivation to eliminate false-normals in female G6PD testing during IVD assay development.
What Technical Challenges Do Pseudogenes Pose In Cyp2D6 Genotyping? Key Ivd Solutions
Discover how pseudogenes interfere with CYP2D6 genotyping assays and how IVD kit designers engineer high specificity into diagnostic kits.
Why Is Discriminating Core Variants Critical In Cyp2D6 Genotyping? Avoid Phenotype Misclassification
Discover why resolving CYP2D6 core variants vs. sub-alleles is critical for accurate metabolizer phenotype prediction & safer PGx assay design.
What Technical Challenges And Pseudogene Interferences Affect Pgx Assay Design? Solutions
Learn how to overcome pseudogene interference (CYP2D6), CNVs, and GC-rich regions in PGx assay design with advanced IVD chemistry and strategies.
How Are Metabolic Phenotypes Classified In Pgx Assays? Master Target Variant Selection For Accuracy
Learn how PGx assays classify metabolic phenotypes and why strategic target variant selection is essential for reliable clinical performance.
Why Is Understanding Prodrug Metabolic Activation Critical When Developing Pharmacokinetic Diagnostic Panels? Guide
Discover why prodrug metabolic activation is critical in PK diagnostic panel design to ensure therapeutic efficacy and avoid safety blind spots.
How Do Genotype And Phenotype Testing Strategies Differ In Pharmacogenetic Ivd Design? Specimen & Assay Guide
Compare genotype vs. phenotype testing in pharmacogenetic IVD design. Learn key differences in specimen stability, handling, and assay trade-offs.
What Technical And Clinical Principles Guide Cdx Assay Design? Master Targeted Therapy Development
Discover core technical and clinical principles for designing companion diagnostic (CDx) assays that reliably guide targeted cancer therapies.
What Are The Trade-Offs Between Genotype And Phenotype Testing In Pgx Ivd Assays? Key Developer Insights
Compare genotype and phenotype testing for PGx IVD assay development, evaluating sample stability, reproducibility, and operational trade-offs.
Why Is Fetal Fraction Measurement A Critical Qc Parameter In Cfdna Assay Development? Prevent Nipt False Negatives
Learn why fetal fraction QC is critical in cfDNA & NIPT assay development to eliminate false-negative risks and ensure clinical diagnostic accuracy.
How Do Cffdna And Maternal Dna Size Differences Influence Nipt Assay Design? Ivd Guide
Learn how cffDNA fragment size differences (~142 bp vs 166 bp) impact NIPT assay design, fetal fraction enrichment, and IVD performance.
What Strategies Optimize Signal-To-Noise Ratio In Ngs Nipt Ivds? 3 Keys To High-Sensitivity Variant Detection
Optimize signal-to-noise ratio in NGS-based NIPT assays using targeted capture, locus depth calibration, and GC bias correction strategies.
What Pre-Analytical Guidelines Optimize Cffdna Yield & Stability For Nipt? Essential Ivd Assay Prep Strategies
Learn essential pre-analytical guidelines for NIPT: blood collection chemistry, plasma purity, size-selective cffDNA extraction, and QC controls.
What Design Considerations & Bioinformatic Steps Optimize Signal-To-Noise Ratio In Ngs Nipt Assays? Expert Guide
Learn how targeted capture chemistry, depth calibration, and GC-normalization optimize signal-to-noise ratios in NGS-based NIPT assays.
How Can Diagnostic Developers Incorporate Internal Fetal Controls In Nipt Workflows To Validate Negative Results?
Learn how NIPT developers use epigenetic markers, SNP panels, and Y-targets to quantify fetal fraction and eliminate false-negative results.
What Technical Strategies Can Assay Developers Implement To Suppress Maternal Dna Interference In Fetal Mutation Assays?
Learn key strategies like PNA clamping, minisequencing, dPCR, and RHDO to suppress maternal background and accurately detect fetal single-gene mutations.
Why Is Short-Fragment Optimization Critical For Cffdna Diagnostic Assays? Boost Sensitivity
Discover why optimizing DNA extraction and PCR primer design for <100 bp short fragments is essential to maximize cffDNA diagnostic sensitivity.
How Do Sample Collection & Processing Impact Cffdna Fetal Fraction? Key Guidelines For Nipt Assays
Learn how sample collection, EDTA vs. stabilizing tubes, and double centrifugation protect fetal DNA fraction in cffDNA and NIPT assay development.
What Biological Factors Contribute To Discordant Nipt Screening Results? A Guide For Ivd Manufacturers
Learn how biological factors like CPM and low fetal fraction cause discordant NIPT results, and how IVD manufacturers can optimize kit validation.
What Is The Biological Mechanism Of Non-Invasive Fetal Rhd Genotyping? Guide To Ivd Assay Design
Learn the biological mechanism of fetal RhD genotyping and how to design high-sensitivity, robust molecular diagnostic assays.
How Do Cffdna And Maternal Cfdna Fragment Sizes Differ? Key Insights For Nipt Developers
Explore the 20-bp size gap between cffDNA (~142 bp) and maternal cfDNA (~166 bp) and how to leverage it for optimized NIPT assay design.
What Factors Optimize Ddpcr For Low-Abundance Ctdna In Ivd? Master 5 Pillars For Clinical-Grade Sensitivity
Learn 5 critical factors to optimize ddPCR assays for low-abundance ctDNA detection in IVD development, from partition integrity to dMIQE.
What Role Does Dsdna Quantification Play In Ivd Development? Ensure Assay Precision With Qc Raw Materials
Learn how fluorometric dsDNA quantification and high-purity IVD quality control raw materials drive assay accuracy and batch-to-batch consistency.
Why Is Standardizing Cell-Free Dna (Cfdna) Extraction Kits Essential When Designing Molecular Diagnostic Assays?
Learn why standardizing cfDNA extraction chemistry is critical for assay sensitivity, LOD control, and successful IVD clinical validation.
How Does Anticoagulant Choice Impact Liquid Biopsy Ivd Prep & Selection Criteria?
Learn how EDTA, heparin, and citrate affect cfDNA preservation in liquid biopsy IVDs, plus key selection criteria for assay sensitivity.
How Do Ctdna Fragmentation Profiles And Tissue Origins Influence Reagent Selection And Workflow Optimization?
Learn how ctDNA fragment sizes and tissue origins dictate reagent selection, extraction chemistries, and workflow design for liquid biopsy assays.
What Fundamental Biological Properties Of Cell-Free Fetal Dna (Cffdna) Must Be Accounted For In Nipt Reagent Design?
Explore how cffDNA fragmentation, half-life, and low abundance dictate raw material selection and reagent formulation for high-performance NIPT assays.
What Preanalytical Factors & Anticoagulants Are Critical For Cfdna Ivd Assays? Key Rules For Sensitivity
Discover critical preanalytical factors in cfDNA IVD assay development, from EDTA plasma selection to cellular stabilization & processing rules.
What Strategies Are Required For Single-Cell Genomic Profiling Of Ctcs? Essential Optimization Workflow
Learn critical pre-analytical and assay optimization strategies for single-cell genomic profiling of CTCs, from sample stabilization to WGA.
What Technical Factors Must Diagnostic Assay Developers Evaluate When Designing Rt-Pcr Assays For Ctc Biomarkers?
Learn key technical factors for designing sensitive RT-PCR assays for CTC biomarkers like CK-19 and AR-V7, from RNA capture to enzyme selection.
What Are The Primary Differences Between Developing Ctdna Assays Vs Ctc Workflows? Key Ivd Insights
Compare ctDNA and CTC liquid biopsy workflows. Explore key differences in pre-analytics, sensitivity, automation, and biological insights for IVD.
How To Eliminate False-Positive Ctdna Calls Caused By Chip? Master Paired Wbc-Plasma Sequencing Workflows
Learn how to eliminate CHIP-driven false positives in liquid biopsy assays using paired WBC-plasma sequencing and subtractive bioinformatic tools.
What Sensitivity And Target Coverage Parameters To Prioritize For Nsclc Ctdna Assays? Lod & Depth Guide
Learn how to balance 0.05-0.1% VAF sensitivity, ultra-deep sequencing, and key driver target selection for NSCLC ctDNA liquid biopsy assays.
What Are The Key Technical And Biological Differences Between Ctcs And Ctdna? Liquid Biopsy Ivd Design Guide
Explore key technical and biological differences between CTCs and ctDNA to optimize liquid biopsy IVD assay design, workflows, and sensitivity.
What Quantification Methods And Standards Are Required To Ensure Analytical Accuracy In Ccfdna Assay Development?
Learn how fluorometric assays, dPCR, microfluidics, and standardized controls ensure accuracy and prevent false negatives in ccfDNA assay development.
What Preanalytical Variables In Ctdna Liquid Biopsy Must Developers Control? Ensure Assay Accuracy
Discover critical preanalytical controls in ctDNA liquid biopsy design, from collection tubes to fragment-size extraction recovery.
How Do Biological Anatomical Barriers Influence Fluid Selection For Primary Brain Tumor Liquid Biopsy Ivds?
Learn how the blood-brain barrier impacts ctDNA release, CSF vs. plasma selection, and extraction reagent design for brain tumor liquid biopsy IVDs.
What Preanalytical & Qc Considerations Are Essential For Ctdna Liquid Biopsy Assays? 4 Key Steps For Ivd Developers
Learn critical preanalytical and QC strategies for ctDNA liquid biopsy assays, from collection tubes to extraction and dPCR controls.
Why Is Edta Plasma Preferred Over Serum As The Sample Matrix When Developing Quantitative Ctdna Diagnostic Assays?
Discover why EDTA plasma outperforms serum in ctDNA assays by preventing leukocyte lysis, maintaining low background noise, and boosting sensitivity.
What Biomarker Strategies Suit Melanoma Ctc Assays? Master Non-Epithelial Ivd Design
Learn key biomarker and raw material strategies for melanoma CTC assays, including GM2/GD2 capture and multiplex mRNA panels for high sensitivity.
How Does Ar-V7 Detection In Ctcs Inform Predictive Diagnostic Assay Design? Optimizing Ivd Performance
Learn how CTC-based AR-V7 detection guides prostate cancer molecular assay design, solving technical challenges in specificity and raw material selection.
What Unique Diagnostic Advantages Does Ctc Expression Profiling Offer Over Ctdna Analysis In Ivd Kit Development?
Discover how CTC expression profiling captures real-time mRNA, protein, and resistance data beyond static ctDNA analysis in IVD kit design.
Why Is Ctc Molecular Characterization Essential Alongside Primary Biopsy In Breast Cancer Ivd Assays?
Learn why CTC molecular characterization is essential in breast cancer IVD assays to capture real-time biomarker shifts and resistance.
Why Is Real-Time Monitoring Of Ctc Biomarker Heterogeneity Critical For Cdx Assay Development? Unlock Dynamic Cdx
Discover why real-time CTC biomarker heterogeneity monitoring is essential for CDx development to track tumor evolution and expand patient eligibility.
What Is The Clinical Value Of Ck-19 Mrna Detection In Ctcs? Key Assay Design & Diagnostic Insights
Learn the clinical value of CK-19 mRNA detection in CTCs and essential molecular assay formulation strategies for robust diagnostic performance.
What Are The Primary Functional Differences Between Ctdna Profiling And Ctc Characterization? Assay Design Guide
Compare ctDNA profiling and CTC characterization in liquid biopsy design. Learn key differences in sample, workflow, and biological insights.
How Do Ctcs Use Pd-L1 & Cd47 For Immune Evasion? Key Insights For Assay Design
Explore how CTCs use PD-L1 and CD47 for immune evasion and learn strategies for building sensitive, multi-marker liquid biopsy assays.
How Can Multiplex Rt-Qpcr Assays Be Designed For Ctc Detection To Minimize False Positives Caused By Background Blood Cells?
Learn how combining orthogonal molecular targets, high-fidelity enzymes, and strict normalization in multiplex RT-qPCR eliminates false positive CTC signals.
What Marker Panel & Fluorophore Considerations Are Key For Ctc Assays? Ensure Robust Diagnostic Design.
Learn key marker choices, fluorophore selection, and buffer optimizations to design highly specific immunofluorescent CTC identification assays.
What Are The Technical Trade-Offs In Ctc Isolation? Microfiltration Vs. Immunoaffinity
Explore key trade-offs between size-based microfiltration and immunoaffinity enrichment for CTC IVD kits, including purity, yield, and reagent design.
How Does Emt Impact Immunomagnetic Ctc Isolation? Key Raw Material Strategies For Kit Developers
Learn how EMT causes EpCAM loss in CTC isolation and discover raw material strategies like multi-marker panels and negative depletion for IVD kits.
How Do Ctcs Utilize Cd47 And Pd-L1? Diagnostic Significance For Immunotherapy Assays
Explore how CTCs use CD47 and PD-L1 for immune evasion and learn key strategies for developing functional liquid biopsy immunotherapy assays.
Why Might Epcam Ctc Assays Fail? Design Multiplex Panels To Overcome Emt
Discover why EpCAM CTC assays miss EMT tumor cells and how IVD developers design multiplex diagnostic panels to eliminate false negatives.
What Are Physical And Biological Ctc Enrichment Strategies? Optimize Your Ivd Assay Design
Compare physical and biological CTC enrichment strategies to optimize sensitivity, purity, and EMT coverage in immunoaffinity IVD assay design.
What Parameters To Evaluate When Selecting Magnetic Particles & Antibodies For Automated Cell Isolation?
Learn key parameters for selecting magnetic particles and antibodies in automated cell isolation for optimal yield, purity, and viability.
How Can Developers Capture Missing Mesenchymal Ctcs? 3 Strategies For Ivd Liquid Biopsy Assays
Learn 3 strategies to capture missing mesenchymal CTCs in liquid biopsy: multi-marker panels, physical separation, and negative depletion.
When Developing An Immunomagnetic Assay For Ctc Isolation, What Are Positive Vs. Negative Selection Trade-Offs?
Compare positive vs. negative immunomagnetic selection for CTC isolation. Discover key trade-offs in purity, heterogeneity, and assay design.
How Can Diagnostic Assay Developers Combine Reagents For Ctdna, Ctcs, And Exosomes To Build Multi-Analyte Panels?
Learn how to combine ctDNA, CTC, and exosome reagents into high-accuracy multi-analyte liquid biopsy panels with standardized workflows.
What Key Technical Challenges Must Ivd Developers Overcome When Designing Ctc Reagents? Solve Rare Cell Assay Hurdles
Explore technical challenges in CTC isolation and profiling. Learn key trade-offs in EpCAM capture, cell integrity, and ultra-sensitive IVD reagents.
Why Is Pre-Analytical And Analytical Standardization Critical When Developing Liquid Biopsy Ivd Assays For Ctcs & Ctdna?
Learn why pre-analytical and analytical standardization is essential for liquid biopsy IVD assays to ensure high sensitivity and reproducible results.
How Do Somatic Mutations In Idh1 And Idh2 Alter Cellular Metabolism? Key Diagnostic Assay Insights
Learn how neomorphic IDH1/2 mutations produce 2-HG oncometabolites and why this mechanism is critical for targeted IVD molecular assay design.
What Key Biological And Methodological Principles Should Assay Developers Consider When Designing Molecular Clonality Tests?
Explore core principles for designing molecular clonality tests in lymphoproliferative disorders, from V(D)J targets to PCR vs. NGS technologies.
How Does V(D)J Recombination Enable Clonality Testing & Kit Primer Design?
Learn how V(D)J recombination enables lymphoid clonality testing and explore critical primer design considerations for accurate IVD diagnostic kits.
What Challenges Exist With Paired Normal Controls In Hematologic Ngs Panels? Master Validation Strategies
Learn why paired normal controls fail in hematologic NGS panels and explore practical validation strategies like FACS and bioinformatic filtering.
What Is The Technical Principle And Detection Strategy For Flt3-Itd Assays In Ivd Kit Development?
Explore FLT3-ITD assay principles, capillary electrophoresis strategies, high-fidelity polymerases, and precise allele ratio calculation for IVD kits.
How To Select Between Pcr, Sanger, And Ngs For Single Gene Assays? Platform Selection
Compare allele-specific PCR, Sanger sequencing, and NGS for single gene assay design. Pick the right platform by VAF sensitivity and target breadth.
How Does Somatic Hypermutation Affect Consensus Primer Performance? Solutions For B-Cell Clonality Assays.
Discover how somatic hypermutation impacts B-cell clonality assays and master primer multiplexing strategies to eliminate false-negative IVD results.
Why Transition From Ce To Ngs For Lymphoid Clonality Testing? Unlock High-Resolution Diagnostic Accuracy
Learn why developers are shifting from CE to NGS for lymphoid clonality testing, eliminating false results and enabling MRD sensitivity down to 0.001%.
How To Distinguish Somatic Mutations From Homopolymer Artifacts In Asxl1 Exon 12? Proven Diagnostic Strategies.
Learn key strategies like high-fidelity polymerases, UMIs, and reference standards to separate somatic mutations from homopolymer artifacts.
Overcoming High Gc-Content Challenges In Cebpa Sequencing: Solutions For Assay Developers
Discover how to overcome PCR bias, target dropout, and uneven coverage in GC-rich targets like CEBPA using optimized enzymes and smart workflows.
Why Include Idh1, Idh2, And Tet2 In Myeloid Diagnostic Panels? Guide Precision Therapy
Explore why IDH1, IDH2, and TET2 targets are essential in myeloid CDx panels to uncover DNA hypermethylation and guide targeted AML therapy.
How Should Molecular Diagnostic Panels For Mpns Address Jak2, Calr, And Mpl Mutations? Optimize Diagnostic Reflex
Learn how leveraging the mutual exclusivity of JAK2, CALR, and MPL mutations optimizes MPN diagnostic workflows, prognostic value, and costs.
What Are The Molecular Characteristics And Methodology Considerations For Flt3 Assay Design In Aml? Expert Guide
Explore FLT3-ITD & TKD molecular traits, PCR methodology, allelic ratio quantification, and design considerations for AML diagnostic assays.
How Do Ngs, Qpcr, And Cytogenetics Compare In Hematopoietic Assay Design? Key Platform Trade-Offs Explained.
Compare targeted NGS, qPCR, and cytogenetics for hematopoietic neoplasm assay design. Learn sensitivity, breadth, and structural detection trade-offs.
How Do Ngs Panels Compare With Qpcr, Fish & Snp Arrays In Myeloid Diagnostic Assay Development?
Compare targeted NGS, qPCR, FISH, and SNP arrays for myeloid neoplasm assay development. Learn key strengths, VAF limits, and strategic roles.
What Are The Advantages Of Break-Apart Fish Probes In Diagnostic Kit Development? Superior Fusion Detection
Explore the structural and clinical advantages of break-apart FISH probes over PCR & karyotyping for molecular diagnostic assay development.
How Do Hydrolysis Probe-Based Qrt-Pcr Assays Function In Mrd Monitoring? Key Developer Criteria
Learn how hydrolysis probe-based qRT-PCR assays detect MRD in leukemia and the key performance criteria diagnostic developers must meet for accuracy.
How Do Snp Arrays Complement Fish & Karyotyping In Mds? Optimize Assay Yield
Discover how array-based SNP genotyping complements FISH and karyotyping to detect CN-LOH and resolve cryptic variants in MDS assay design.
What Are The Advantages Of Break-Apart Fish Probe Designs For Kmt2A Ivd Assays?
Learn how break-apart FISH probes streamline KMT2A (MLL) IVD assay development, simplify regulatory validation, and lower manufacturing costs in AML.
Why Do Bcr-Abl1 Rt-Pcr Kits Miss Rare Cml Variants? Optimize Probe & Reflex Strategies
Discover why standard BCR-ABL1 RT-PCR kits miss rare e19a2/p230 CML variants and how to optimize probe coverage with dual-color FISH reflex testing.
What Are Key Target Regions & Diagnostic Strategies For Pml-Rara Assay Design? Optimize Apl Ivd
Explore key PML-RARA breakpoint targets (bcr1-3) and diagnostic strategies pairing FISH for rapid APL diagnosis with RT-qPCR for MRD tracking.
How Do Breakpoint Distribution Patterns Influence T(11;14) Mcl Test Selection? Fish Vs. Pcr Diagnostic Guide
Learn how the 350-kb breakpoint spread of t(11;14) makes locus-spanning FISH and IHC essential over standard PCR in mantle cell lymphoma diagnostics.
What Bcl2 Locus Limitations Impact T(14;18) Pcr Assays? Key Ivd Design Insights
Discover how BCL2 locus architecture creates PCR blind spots in t(14;18) assays and how to design accurate IVD diagnostic strategies.
How Are Recurrent Chromosomal Translocations Diagnosed In Hematological Malignancies? Key Methods & Ivd Raw Materials
Explore diagnostic methods (FISH, RT-qPCR, MPS) and essential IVD raw materials for recurrent chromosomal translocations in hematological malignancies.
Why Is High Sequencing Coverage Critical For Solid Tumor Ngs Panels? Ensure Rare Variant Call Accuracy
High sequencing coverage in solid tumor NGS detects low-frequency somatic mutations in low-purity samples, ensuring reliable clinical diagnostics.
Why Is Liquid Biopsy Essential In Modern Cancer Diagnostic Assay Development? Master Specimen Selection Today
Explore why liquid biopsy is essential for cancer diagnostic assays, compare key specimens (plasma, urine, stool, fluids), and solve assay challenges.
How Does Tissue-Specific Biology Impact Targeted Gene Panels? Key Assay Design Principles
Learn how tissue biology and compensatory signaling impact solid tumor gene panels. Discover key NGS panel design insights for IVD developers.
What Technical Bottlenecks Occur In Multiplex Pcr Primer Design For Ffpe Dna? Overcome Ivd Challenges
Learn how IVD developers overcome FFPE DNA multiplex PCR primer design bottlenecks like primer-dimers, Tm mismatch, and amplicon competition.
What Key Sample Quality And Assay Workflow Considerations Are Required When Developing Rna-Seq Assays For Degraded Ffpe Tumor Samples?
Learn key workflow considerations for FFPE RNA-seq assays, from acidic cross-link reversal and fluorometry to targeted hybridization capture.
How Do Target Size & Dna Input Dictate Hyb Capture Vs Pcr In Ngs? Optimize Solid Tumor Panel Design
Compare hybridization capture vs. multiplex PCR for solid tumor NGS panels based on target region size, sample DNA input, and assay objectives.
What Are The Advantages Of Hybridization Capture Vs Pcr For Solid Tumor Panels? Essential Assay Design Insights
Explore hybridization capture vs. PCR hotspot testing for solid tumor gene panels. Discover key technical advantages and assay design considerations.
Why Is High Sequencing Depth Critical When Designing Mps Panels For Solid Tumor Diagnostics? Ensure Assay Accuracy
Learn why 300x-1000x depth in solid tumor MPS panels is critical to overcome tumor heterogeneity, low cellularity, and prevent false negatives.
